Compile Data Set for Download or QSAR
Report error Found 89 Enz. Inhib. hit(s) with all data for entry = 6978
TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163075(US9062026, Table III, Compound 3)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163080(US9062026, Table III, Compound 8)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163081(US9062026, Table III, Compound 9)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163082(US9062026, Table III, Compound 10)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163088(US9062026, Table III, Compound 16)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163089(US9062026, Table III, Compound 17)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163085(US9062026, Table III, Compound 13)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163086(US9062026, Table III, Compound 14)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163087(US9062026, Table III, Compound 15)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163097(US9062026, Table III, Compound 25)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163098(US9062026, Table III, Compound 26)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163092(US9062026, Table III, Compound 20)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163094(US9062026, Table III, Compound 22)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163106(US9062026, Table III, Compound 34)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163100(US9062026, Table III, Compound 28)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163103(US9062026, Table III, Compound 31)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163112(US9062026, Table III, Compound 40)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163113(US9062026, Table III, Compound 41)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163114(US9062026, Table III, Compound 42)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163115(US9062026, Table III, Compound 43)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163108(US9062026, Table III, Compound 36)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163109(US9062026, Table III, Compound 37)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163120(US9062026, Table III, Compound 48)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163121(US9062026, Table III, Compound 49)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163122(US9062026, Table III, Compound 50)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163123(US9062026, Table III, Compound 51)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163116(US9062026, Table III, Compound 44)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163118(US9062026, Table III, Compound 46)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163128(US9062026, Table III, Compound 56)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163129(US9062026, Table III, Compound 57)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163130(US9062026, Table III, Compound 58)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163131(US9062026, Table III, Compound 59)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163125(US9062026, Table III, Compound 53)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163126(US9062026, Table III, Compound 54)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163127(US9062026, Table III, Compound 55)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163136(US9062026, Table III, Compound 79 | US9062026, Tab...)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163137(US9062026, Table III, Compound 65)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163138(US9062026, Table III, Compound 66)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163139(US9062026, Table III, Compound 67)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163132(US9062026, Table III, Compound 60)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163133(US9062026, Table III, Compound 61)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163134(US9062026, Table III, Compound 62)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163144(US9062026, Table III, Compound 72)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163145(US9062026, Table III, Compound 73)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163146(US9062026, Table III, Compound 74)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163147(US9062026, Table III, Compound 75)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163140(US9062026, Table III, Compound 68)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163141(US9062026, Table III, Compound 69)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163142(US9062026, Table III, Compound 70)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

TargetTransitional endoplasmic reticulum ATPase(Human)
Cleave Biosciences

US Patent
LigandPNGBDBM163143(US9062026, Table III, Compound 71)
Affinity DataIC50: 2.00E+3nMpH: 7.5 T: 2°CAssay Description:The ATPase assay is performed according the following protocol: Purified enzyme (20 nM p97), substrate (20 uM ATP) and a dose titration of compounds ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/9/2016
Entry Details
US Patent

Displayed 1 to 50 (of 89 total ) | Next | Last >>
Jump to: